ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable or
NCT04730388 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2021-01-29
Summary
Evaluation of the efficacy and safety of the combination ATEZOLIZUMAB - BEVACIZUMAB in the treatment of locally advanced inoperable or metastatic hepatocellular carcinoma in Finistère
Conditions
Sponsors & Collaborators
-
University Hospital, Brest
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-01-18
- Primary Completion
- 2022-01-18
- Completion
- 2022-01-18
More Related Trials
-
Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC
NCT07018947 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
NCT05168163 ·Status: RECRUITING ·Phase: PHASE2
-
Atezolizumab Plus Bevacizumab With HCC and HBV Infection
NCT04180072 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
NCT06117891 ·Status: ACTIVE_NOT_RECRUITING
-
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
NCT05359861 ·Status: COMPLETED ·Phase: PHASE2
-
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
NCT00365391 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
NCT04487067 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma
NCT04829383 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
NCT04102098 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma
NCT06806579 ·Status: RECRUITING
-
Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma
NCT06138769 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
NCT07047586 ·Status: RECRUITING ·Phase: PHASE2
-
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
NCT06096779 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer
NCT05211323 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study.
NCT04378023 ·Status: RECRUITING
-
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
NCT03755791 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma
NCT01210495 ·Status: COMPLETED ·Phase: PHASE2
-
Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma
NCT06254248 ·Status: RECRUITING ·Phase: PHASE2
-
Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
NCT00287222 ·Status: COMPLETED ·Phase: PHASE2
-
Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation
NCT05833126 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
NCT06530251 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
NCT03847428 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
NCT05173298 ·Status: RECRUITING
-
Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma
NCT05109052 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
NCT04721132 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2